News

WuXi News

Filter By

2020/11/18

WuXi Advanced Therapies Expands Philadelphia Campus with New State-of-The-Art Testing Laboratory

November 18, 2020 - Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) – a business unit of WuXi AppTec offering end-to-end contract services for the cell and gene therapies industry – today announced the completion of a facility expansion that will triple its advanced testing capacity at the company’s Philadelphia Navy Yard campus. The expanded laboratory will provide much needed testing services for cell and gene therapy and biotherapy clients globally. This will especially enable WuXi ATU to provide fully integrated contract testing, development and manufacturing services for advanced therapies clients and thus advance its mission to bring life-saving treatments to patients in need in the shortest possible turn-around-time, and assured quality and quantity.

Read more

2020/11/12

WuXi Advanced Therapies Expands Services to Include High-Quality and Cost-Effective R&D and GMP Plasmid DNA

November 12, 2020 – Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide high-quality and cost-effective supplies of R&D and GMP Plasmids. WuXi ATU is a business unit of WuXi AppTec and a leading global Contract Testing, Development and Manufacturing Organization (CTDMO) offering end-to-end contract services for the cell and gene therapy industry. With these enhanced capabilities, WuXi ATU can assist customers worldwide in overcoming current plasmid DNA supply constraints by providing a direct source and expediting the R&D and manufacturing process of cell and gene therapy applications.

Read more

2020/10/29

WuXi AppTec Reports Strong Third-Quarter 2020 Results

SHANGHAI, Oct. 29, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2020 ("Reporting Period").

Read more

2020/08/13

WuXi AppTec Achieved Strong Growth in First-Half of 2020 with China Sites Resuming Full Operations

(SHANGHAI, August 13, 2020) — WuXi AppTec Co., Ltd. (stock code: 603259.SH / 2359.HK), a company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its reviewed financial results for the first half of 2020 (Reporting Period).

Read more

2020/06/01

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

SHANGHAI and PHILADELPHIA, June 1, 2020 -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announced today the appointment of Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy Contract Development and Manufacturing Organization (CDMO). In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services.

Read more